Zepbound

Zepbound (generic name: tirzepatide) is a once-weekly injectable prescription medication approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia. It is manufactured by Eli Lilly and Company.

How It Works

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — the first of its kind approved for weight management. According to the FDA-approved prescribing information, it activates both the GIP and GLP-1 receptors simultaneously. GLP-1 receptor activation slows gastric emptying (meaning food moves more slowly out of the stomach), reduces appetite signals in the brain, and promotes feelings of fullness. GIP receptor activation is believed to complement these effects by influencing fat tissue metabolism and further modulating appetite. Together, these two mechanisms reduce caloric intake and support sustained weight loss. Tirzepatide is structurally based on the native GIP hormone sequence and is administered subcutaneously once weekly.

Side Effects by Week

Most Common Side Effects

• Nausea: Reported in up to 31% of patients in the SURMOUNT-1 trial at the 15 mg dose; most frequently occurs during dose escalation periods.
• Diarrhea: Occurred in approximately 23% of patients receiving 15 mg tirzepatide in SURMOUNT-1; generally mild to moderate in severity.
• Vomiting: Reported in approximately 20% of patients at the 15 mg dose in SURMOUNT-1; most common during the first weeks of therapy.
• Constipation: Occurred in approximately 17% of patients in SURMOUNT-1; results from slowed gastric motility caused by the drug's mechanism.
• Abdominal pain: Reported in roughly 10% of patients in SURMOUNT-1; typically described as cramping or discomfort.
• Injection-site reactions: Including redness, bruising, itching, and swelling; listed in FDA prescribing information as common local adverse events.
• Decreased appetite: Expected pharmacological effect; reported by a large proportion of participants across all SURMOUNT trials.
• Fatigue: Reported during early treatment phases in SURMOUNT-1 trial data; generally transient.
• Dyspepsia (indigestion) and belching: Listed in the FDA-approved prescribing information as common adverse reactions.
• Hair loss: Reported in SURMOUNT-1 as alopecia; attributed primarily to rapid weight loss and caloric restriction (telogen effluvium) rather than a direct drug effect.

Serious Side Effects

• ⚠️ BOXED WARNING — Thyroid C-Cell Tumors: The FDA prescribing information for Zepbound carries a boxed warning stating that tirzepatide caused thyroid C-cell tumors in rodents; it is unknown whether this applies to humans. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• ⚠️ Pancreatitis: Acute pancreatitis, including fatal cases, has been reported with GLP-1 receptor agonists; FDA labeling advises discontinuing Zepbound if pancreatitis is suspected and not restarting if confirmed.
• ⚠️ Acute Gallbladder Disease: Cholelithiasis (gallstones) and cholecystitis have been reported; FDA labeling notes that substantial or rapid weight loss is a known risk factor for gallstone formation.
• ⚠️ Hypoglycemia (with concomitant insulin secretagogues or insulin): FDA prescribing information warns of serious hypoglycemia risk when Zepbound is used alongside insulin or sulfonylureas; dose reductions of those agents may be required.
• ⚠️ Acute Kidney Injury: Reported in post-marketing experience with GLP-1 receptor agonists; dehydration from GI side effects is a contributing factor per FDA labeling.
• ⚠️ Hypersensitivity Reactions: Serious reactions including anaphylaxis and angioedema have been reported; FDA labeling states patients experiencing such reactions should discontinue Zepbound and seek emergency care.
• ⚠️ Diabetic Retinopathy Complications: FDA labeling notes reports of worsening diabetic retinopathy in patients with type 2 diabetes treated with tirzepatide; monitoring is recommended for patients with this history.
• ⚠️ Suicidal Ideation and Behavior: FDA prescribing information instructs monitoring for emergence or worsening of depression, suicidal thoughts, or unusual mood changes; patients should report any such symptoms promptly.
• ⚠️ Heart Rate Increase: Mean increases in resting heart rate of approximately 2–4 beats per minute were observed in SURMOUNT clinical trials; FDA labeling advises monitoring in patients with known cardiac conditions.

Managing Side Effects

Nausea

According to SURMOUNT-1 trial data, nausea was most prevalent during dose escalation steps and generally decreased over time. Practical strategies include eating smaller portions, choosing low-fat and low-odor foods, eating slowly and stopping when satiated, avoiding lying down immediately after eating, and staying well hydrated. Ginger-containing products have anecdotal support but are not endorsed in FDA labeling. If nausea is severe or persistent, the prescribing information supports temporarily delaying a dose escalation step.

Vomiting

Vomiting was reported most frequently in the first weeks of treatment in SURMOUNT clinical trials. Adequate hydration is critical to prevent dehydration and secondary kidney injury noted in FDA labeling. Patients should contact their prescriber if vomiting prevents oral fluid intake or lasts more than 24 hours. FDA labeling supports dose escalation delays if GI tolerability is poor.

Constipation

Constipation results from tirzepatide's mechanism of slowing gastric and intestinal motility, as described in FDA prescribing information. Increasing dietary fiber (fruits, vegetables, whole grains) and fluid intake are standard approaches. Physical activity may support bowel regularity. Patients should discuss the use of fiber supplements or osmotic laxatives with their prescriber; FDA labeling does not specifically endorse particular OTC products.

Diarrhea

Diarrhea was reported in approximately 23% of patients receiving 15 mg tirzepatide in SURMOUNT-1. Maintaining hydration is the primary concern. Patients should avoid high-fat and high-sugar foods that may worsen loose stools. If diarrhea is persistent or accompanied by signs of dehydration (dizziness, dark urine), medical attention is warranted per FDA labeling guidance on acute kidney injury.

Injection-Site Reactions

FDA prescribing information recommends rotating injection sites with each weekly dose among the abdomen, thigh, or upper arm. Avoid injecting into areas that are tender, bruised, red, or hardened. Allowing the pen to reach room temperature before injecting may reduce discomfort.

Hair Thinning

Alopecia was reported as an adverse event in SURMOUNT-1. Based on the pattern observed in clinical trials, hair thinning appears to be consistent with telogen effluvium — a temporary shedding triggered by rapid caloric restriction and weight loss rather than a direct toxic drug effect. Ensuring adequate protein intake is frequently discussed in clinical settings; patients experiencing significant hair loss should notify their prescriber to rule out other causes.

Hypoglycemia

FDA labeling specifically warns that patients taking Zepbound concurrently with insulin or sulfonylureas face increased hypoglycemia risk. Patients should know the symptoms of low blood sugar (shakiness, sweating, confusion, rapid heartbeat) and have a plan for treatment. Dose adjustments of the concurrent diabetes medications may be required; this must be managed by a prescriber.

Cost and Access in 2026

Frequently Asked Questions